



**PPG-CM**

Programa de Pós-Graduação  
em Ciências Médicas

**PLANO DE ENSINO**  
**SEMESTRE 2023/ 1**

**I. IDENTIFICAÇÃO DA DISCIPLINA: Mediadores da resposta Inflamatória**

CÓDIGO	NOME DA DISCIPLINA	Alunos	CRÉDITOS	TOTAL DE HORAS-AULA SEMESTRAIS
PCM 3010000	Mediadores da Resposta Inflamatória	Mestrado e Doutorado	03	45

**I.HORÁRIO**

**SEXTAS-FEIRAS DAS 14:00 AS 18:00 HS**

**II. PROFESSOR (ES) MINISTRANTE (S)**

Profª Drª.Tânia Silvia Fröde  
E-mail: taniafrode@gmail.com

**III. EMENTA:**

Entender a fisiopatologia da inflamação, conhecer os principais mediadores envolvidos na resposta inflamatória e correlacionar com várias doenças de caráter inflamatório

**IV. OBJETIVOS**

**Objetivos Gerais:** Capacitar o acadêmico a conhecer e discutir sobre os principais mediadores envolvidos no processo inflamatório

**Objetivos Específicos:**

- 1) Conhecer sobre a liberação e a expressão de mediadores inflamatórios por células envolvidas na resposta imune inata
- 2) Conhecer sobre os fatores de transcrição nuclear de células da resposta imune inata
- 3) Conhecer sobre os principais mecanismos envolvidos na apoptose celular
- 4) Conhecer sobre as principais vias de sinalização celular (MAPK, JNK etc)
- 5) Conhecer o papel deste processo (mediadores inflamatórios, vias de sinalização ,a apoptose os fatores de transcrição nuclear) na fisiologia das doenças de caráter inflamatório agudo e crônico.
- 6) Conhecer sobre o mecanismo de ação anti-inflamatório de medicamentos atuais e daqueles em desenvolvimento no tratamento de doença de caráter inflamatório

**V. CONTEÚDO PROGRAMÁTICO**

CONTEÚDO PROGRAMÁTICO	HORAS-AULA		ESTRATÉGIA As atividades de ensino ministradas em aula e seminários serão realizadas via online plataforma Moodle (sistema RNP).
1. mediadores inflamatórios	03	02	Seminários via online
2. fatores de transcrição nuclear de células da resposta imune inata	01	02	Seminários via online
3. Doenças neurológicas relacionadas a inflamação	03	03	Seminários via online

4. Doenças reumáticas, endócrinas, cardiovasculares, gastrointestinais e inflamação	03	03	Seminários via online
5. doenças de caráter inflamatório agudo e crônico	03	02	Seminários via online

## VI. METODOLOGIA DE ENSINO / DESENVOLVIMENTO DO PROGRAMA

### Metodologia de ensino

Aulas Teóricas: exposição dialogada online

Recursos utilizados: seminários por Web conferência (plataforma Moodle, sistema RNP)

## VII. METODOLOGIA DE AVALIAÇÃO

### AVALIAÇÃO TEÓRICA

Serão realizadas dois (2) seminários por aluno

### AVALIAÇÃO POR SEMINÁRIO

Cada aluno irá apresentar dois seminários, distribuído pelo professor, por e-mail e inseridos na plataforma Moodle. Estes seminários **serão apresentados via online**. **Nota final:** Avaliação do seminário, nota mínima 7,0, frequência 75%

## VIII- Cronograma

DIA e horário	SEMINARIOS	ALUNO
10.3	Aula mediadores da resposta inflamatória	Tânia Silvia Fröde
17.3	SEMINÁRIOS	ALUNO
24.3	SEMINÁRIOS	ALUNO
31.3	SEMINÁRIOS	ALUNO
14.4	SEMINÁRIOS	ALUNO
28.4	SEMINÁRIOS	ALUNO
5.5	SEMINÁRIOS	ALUNO
12.5	SEMINÁRIOS	ALUNO
20.5	SEMINÁRIOS	ALUNO

## XIX- BIBLIOGRAFIA BÁSICA

ANTONIOLI, L.; COLUCCI, R.; LA MOTTA, C.; TUCCORI, M.; AWWAD, O.; DA SETTIMO, F.; BLANDIZZI, C.; FORNAI, M. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. *Current Drug Targets*, v. 13, n. 6, p. 842-862, 2012.

ANTONIOLI, L.; BLANDIZZI, C.; PACHER, P.; HASKÓ, G. Immunity, inflammation and cancer: a leading role for adenosine. *Nature Reviews Cancer*, v.13, n. 12, p. 842-857, 2013.

ANTONIOLI, L.; CSÓKA, B.; FORNAI, M.; COLUCCI, R.; KÓKAI, E.; BLANDIZZI, C.; HASKÓ, G. Adenosine and inflammation: what's new on the horizon? *Drug Discovery Today*, v. 19, p. 1051-1068, 2014.

ANVARI, F.; SHARMA, A. K.; FERNANDEZ, L. G.; HRANJEC, T.; RAVID, K.; KRON, I. L.; LAUBACH, V. E. Tissue-derived proinflammatory effect of adenosine A<sub>2B</sub> receptor in lung ischemia–reperfusion injury. *The Journal of Thoracic and Cardiovascular Surgery*, v. 140, n. 4, p. 871-877, 2010.

ARNHOLD, J.; FLEMMIG, J. Human myeloperoxidase in innate and acquired immunity. *Archives of Biochemistry and Biophysics*, v. 500, n. 1, p. 92-106, 2010.

- ARTHUR, J. S.; LEY, S. C. Mitogen-activated protein kinases in innate immunity. *Nature Reviews Immunology*, v. 13, n. 9, p. 679-692, 2013.
- ASHLEY, N.T.; WEIL, Z. M.; NELSON, R. J. Inflammation: mechanisms, costs, and natural variation. *Annual Review of Ecology, Evolution, and Systematics*, v. 43, p. 385-406, 2012.
- AYROLDI, E.; CANNARILE, L.; MIGLIORATI, G.; NOCENTINI, G.; DELFINO, D. V.; RICCARDI, C. Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways. *FASEB Journal*, v. 26, n. 12, p. 4805-4820, 2012.
- BARLETTA, K. E.; LEY, K.; MEHRAD, B. Regulation of Neutrophil Function by Adenosine. *Arteriosclerosis, Thrombosis, and Vascular Biology*, v. 32, n. 4, p. 856-64, 2012.
- BATRA, S.; BALAMAYOORAN, G.; SAHOO, M. K. Nuclear Factor- $\kappa$ B: a key regulator in health and disease of lungs. *Archivum Immunologiae et Therapiae Experimentalis*, v. 59, p. 335-351, 2011.
- BRENNER, D.; BLASER, H.; MAK, T. W. Regulation of tumour necrosis factor signalling: live or let die. *Nature Reviews Immunology*, v. 15, n. 6, p. 362-74, 2015.
- CALABRESE, L. H.; ROSE-JOHN, S. IL-6 biology: implications for clinical targeting in rheumatic disease. *Nature Reviews Rheumatology*, v. 10, n. 12, p. 720-727, 2014.
- CALZADO, M. A.; BACHER, S.; SCHMITZ, M. L. NF-kappa B inhibitors for the treatment of inflammatory diseases and cancer. *Current Medicinal Chemistry*, v. 14, n. 3, p. 367-76, 2007.
- CHANG, S. H.; DONG, C. Signaling of interleukin-17 family cytokines in immunity and inflammation. *Cellular Signalling*. v. 23, n. 7, p. 1069-1075, 2011.
- CHOVATIYA, R.; MEDZHITOV, R. Stress, inflammation, and defense of homeostasis. *Molecular Cell*, v. 54, n. 2, p. 281-288, 2014.
- COMMINS, S. P.; BORISH, L.; STEINKE, J. W. Immunologic messenger molecules: Cytokines, interferons, and chemokines. *Journal of Allergy and Clinical Immunology*, v. 125, n. 2, p. S53-S72, 2010.
- CONAGHAN, P. G. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. *Rheumatology International*, v. 32, n. 6, p. 1491-502, 2012.
- CORTÉS, A.; GRACIA, E.; MORENO, E.; MALLOL, J.; LLUÍS, C.; CANELA, E. I.; CASADÓ, V. Moonlighting adenosine deaminase: a target protein for drug development. *Medicinal Research Reviews*, v. 35, n. 1, p. 85-125, 2015.
- DALE, D. C.; BOXER, L.; LILES, W. C. The phagocytes: neutrophils and monocytes. *Blood*, v. 112, n. 4, p. 935-945, 2008.
- DELPORTE, C.; VAN ANTWERPEN, P.; VANHAMME, L.; ROUMEGUÈRE, T.; BOUDJELTIA, K. Z. Low-Density Lipoprotein Modified by Myeloperoxidase in Inflammatory Pathways and Clinical Studies. *Mediators of Inflammation*, v.13, 2013.
- DIAMANT, G.; DIKSTEIN, R. Transcriptional control by NF-kappa B: elongation in focus. *Biochimica et Biophysica Acta*, v. 1829, n. 9, p. 937-945, 2013.

- DITTRICH, A.; HESSENKEMPER, W.; SCHAPER, F. Systems biology of IL-6, IL-12 family cytokines. *Cytokine & Growth Factor Reviews*, v. 26, p. 595-602, 2015.
- DONG, W.; LIU, Y.; PENG, J.; CHEN, L.; ZOU, T.; XIAO, H.; LIU, Z.; LI, W.; BU, Y.; QI, Y. The IRAK-1-BCL10-MALT1-TRAF6-TAK1 cascade mediates signaling to NF-kappa B from Toll-like receptor 4. *Journal of Biological Chemistry*, v. 281, n. 36, p. 26029-26040, 2006.
- DORWARD, D. A.; LUCAS, C. D.; ROSSI, A. G.; HASLETT, C.; DHALIWAL, K. Imaging inflammation: Molecular strategies to visualize key components of the inflammatory cascade, from initiation to resolution. *Pharmacology & Therapeutics*, v. 135, p. 182-199, 2012.
- FONTES, J. A.; ROSE, N. R.; ČIHÁKOVÁ, D. The varying faces of IL-6: From cardiac protection to cardiac failure. *Cytokine*, v. 74, p. 62-68, 2015.
- GASPARINI, C.; CELEGHINI, C.; MONASTA, L.; ZAULI, G. NF-kappa B pathways in hematological malignancies. *Cellular and Molecular Life Sciences*, v. 71, n. 11, p. 2083-2102, 2014.
- GHOSH, S.; ERZURUM, S. C. Nitric oxide metabolism in asthma pathophysiology. *Biochimica et Biophysica Acta*, v. 1810, p. 1008-1016, 2011.
- HAYDEN, M.; GHOSH, S. Regulation of NF- $\kappa$ B by TNF family cytokines. *Seminars in Immunology*, v. 26, n. 3, p. 253-266, 2014.
- HEADLAND, S. E.; NORLING, L. V. The resolution of inflammation: Principles and a challenges. *Seminars in Immunology*, v. 27, p. 149-160, 2015.
- HOENDERDOS, K.; CONDLIFFE, A. The neutrophil in chronic obstructive pulmonary disease. *American Journal of Respiratory Cell and Molecular Biology*. v. 48, p. 531-539, 2013.
- HOESEL, B.; SCHMID, J. A. The complexity of NF- $\kappa$ B signaling in inflammation and cancer. *Molecular Cancer*, v. 12, n. 86, p. 1-15, 2013.
- HOU, C.; LIN, H.; CHANG, C.; HUANG, W.; LIN, M. Oxidative stress and pyrogenic fever pathogenesis. *European Journal of Pharmacology*, v. 667, p. 6-12, 2011.
- IP, W. K.; WONG, C. K.; LAM, C. W. K. Interleukin (IL)-4 and IL-13 up-regulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signalling pathways. *Clinical & Experimental Immunology*, v. 145, n.1, p. 162-172, 2006.
- JOZWIAK-BEBENISTA, M.; NOWAK, J. Z. Paracetamol: mechanism of action, applications and safety concern. *Acta Poloniae Pharmaceutica*, v. 71, n. 1, p. 11-23, 2014.
- KÄLVEGREN, H.; FRIDFELDT, J.; BENGTSSON, T. The role of plasma adenosine deaminase in chemoattractant-stimulated oxygen radical production in neutrophils. *European Journal of Cell Biology*, v. 89, p. 462-467, 2010.
- KANG, S.; TANAKA, T.; KISHIMOTO, T. Therapeutic uses of anti-interleukin-6 receptor antibody. *International Immunology*, v. 27, n. 1, p. 21-29, 2015.
- KATO, Y. Neutrophil myeloperoxidase and its substrates: formation of specific markers and reactive compounds during inflammation, *Journal of Clinical Biochemistry and Nutrition*, v. 58, p. 99-104, 2016.

- KING, E.M.; CHIVERS, J. E.; RIDER, C. F.; MINNICH, A.; GIEMBYCZ M. A.; NEWTON, R. Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms. *PLoS ONE*, v. 8, n. 1, e53936, 2013.
- KOLACZKOWSKA, E.; KUBES, P. Neutrophil recruitment and function in health and inflammation. *Nature Reviews Immunology*, v. 13, p. 159-175, 2013.
- KOLATTUKUDY, P. E.; NIU, J. Inflammation, ER Stress, Autophagy and MCP-1/CCR2 Pathway. *Circulation Research*, v. 110, n. 1, p. 174-189, 2012.
- KVIETYS, P.; GRANGER, D. N. Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. *Free Radical Biology & Medicine*, v. 52, p. 556-592, 2012.
- KUMAR, S.; BOEHM, J.; LEE, J. C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. *Nature Reviews Drug Discovery*, v. 2, n. 9, p. 717-726, 2003.
- LAEV, S. S.; SALAKHUTDINOV, N. F. Anti-arthritic agents: progress and potential. *Bioorganic & Medicinal Chemistry*, v. 23, p. 3059–3080, 2015.
- LARKIN III, J.; AHMED, C. M.; WILSON, T. D.; JOHNSON, H. M. Regulation of interferon gamma signaling by suppressors of cytokine signaling and regulatory T cells. *Frontiers in Immunology*, v. 18, n. 4, p. 1-8, 2013.
- LAROCCA, N. E.; MORENO, D.; GARMENDIA, J. V.; DE SANCTIS, J. B. Inhibitors of phosphoinositol 3 kinase and NF $\kappa$ B for the treatment of chronic obstructive pulmonary disease. *Recent Patents on Inflammation & Allergy Drug Discovery*, v. 5, p. 178-183, 2011.
- LAWRENCE, T. The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harbor Perspectives in Biology*, v. 1, n. 6, p. a001651, 2009.
- LEE, M. R.; DOMINGUEZ, C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38 alpha protein. *Current Medicinal Chemistry*, v. 12, n. 25, p. 2979-2994, 2005.
- MACNEE, W.; ALLAN, R. J.; JONES, I.; DE SALVO, M. C.; TAN, L. F. Efficacy and safety of the oral p38 inhibitor PH- 797804 in chronic obstructive pulmonary disease: a randomized clinical trial. *Thorax*, v. 68, n. 8, p. 738-745, 2013.
- MAK, J. C. W. Pathogenesis of COPD. Part II. Oxidative-antioxidative imbalance. *The International Journal of Tuberculosis and Lung Disease*, v. 12, p. 368-374, 2008.
- MANTOVANI, A.; CASSATELLA, M. A.; COSTANTINI, C.; JAILLON, S. Neutrophils in the activation and regulation of innate and adaptive immunity. *Nature Reviews Immunology*, v. 11, n. 8, p. 519-531, 2011.
- MAO, K.; CHEN, S.; CHEN, M.; MA, Y.; WANG, Y.; HUANG, B.; HE, Z.; ZENG, Y.; HU, Y.; SUN, S.; LI, J.; WU, X.; WANG, X.; STROBER, W.; CHEN, C.; MENG, G.; SUN, B. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. *Cell Research*, v. 23, p. 201-12, 2013.
- MCGETTIGAN, P.; HENRY, D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. *PLoS Medicine*, v. 8, n. 9, p. e1001098, 2011.
- MEDZHITOV, R.; HORNG, T. Transcriptional control of the inflammatory response. *Nature Reviews Immunology*, v. 9, n. 10, p. 692-703, 2009.

METZLER, K. D.; FUCHS, T. A.; NAUSEEF, W. M.; REUMAUX, D.; ROESLER, J.; SCHULZE, I.; WAHN, V.; PAPAYANNOPOULOS, V.; ZYCHLINSKY, A. Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. *Blood*, v. 117, n. 3, p. 953-959, 2011.

MONTSEIRÍN, J. Neutrophils and Asthma. *Journal Investigational Allergology and Clinical Immunology*, v. 19, n. 5, p. 340-354, 2009.

NAGY, G.; CLARK, J. M.; BUZAS, E. I.; GORMAN, C. L.; COPE, A. P. Nitric oxide, chronic inflammation and autoimmunity. *Immunology Letters*, v. 111, p. 1-5, 2007.

NAUSEEF, W. M. Myeloperoxidase in human neutrophil host defense. *Cellular Microbiology*, v. 8, p. 1146-1155, 2014.

NEWTON, K.; DIXIT, V. M. Signaling in innate immunity and inflammation. *Cold Spring Harbor Perspectives in Biology*, v. 4, p. a006049, 2012.

OECKINGHAUS, A.; HAYDEN, M. S.; GHOSH, S. Crosstalk in NF-kappa B signaling pathways. *Nature Immunology*, v. 12, n. 8, p. 695-708, 2011.

PAPAYANNOPOULOS, V.; ZYCHLINSKY, A. NETs: a new strategy for using old weapons. *Trends of Immunology*, v. 30, n. 11, p. 513-521, 2009.

PATRONO, C.; ROCCA, B. Nonsteroidal anti-inflammatory drugs: past, present and future. *Pharmacological Research*, v. 59, n. 5, p. 285-289, 2009.

PAYNE, A. S.; FREISHTAT, R. J. Conserved steroid hormone homology converges on NFkB to modulate inflammation in asthma. *Journal of Investigative Medicine*, v. 60, n. 1, p. 13-17, 2012.

POBER, J. S.; SESSA, W. C. Evolving functions of endothelial cells in inflammation. *Nature Reviews Immunology*, v. 7, p. 803-815, 2007.

PREDONZANI, A.; CALÌ, B.; AGNELLINI, A. H.; MOLON, B. Spotlights on immunological effects of reactive nitrogen species: When inflammation says nitric oxide. *World Journal of Experimental Medicine*, v. 5, n. 2, p. 64-76, 2015.

PROKOPOWICZ, Z.; MARCINKIEWICZ, J.; KATZ, D. R.; CHAIN, B. M. Neutrophil Myeloperoxidase: Soldier and Statesman. *Archivum Immunologiae et Therapiae Experimentalis*, v. 60, n. 1, p. 43-54, 2012.

QUAX, R. A.; MENENSCHIJN, L.; KOPER, J. W.; HAZES, J. M.; LAMBERTS, S. W. J.; van ROSSUM, E. F. C.; FEELDERS, R. A. Glucocorticoid sensitivity in health and disease. *Nature Reviews Endocrinology*, v. 9, n. 11, p. 670-686, 2013.

RAO, P.; KNAUS, E. E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. *Journal Pharmacy and Pharmaceutical Sciences*, v. 11, n. 2, p. 81s-110s, 2008.

RATH, T.; BILLMEIER, U.; WALDNER, M. J.; ATREYA, R.; NEURATH, M. F. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. *Archives of Toxicology*, v. 89, p. 541-554, 2015.

REDINGTON, A. E. Modulation of nitric oxide pathways: Therapeutic potential in asthma and chronic obstructive pulmonary disease. *European Journal of Pharmacology*, v. 533, p. 263-276, 2006.

RINCON, M.; IRVIN, C. G. Role of IL-6 in asthma and other inflammatory pulmonary diseases. *International Journal of Biological Sciences*, v. 8, n. 9, p. 1281-1290, 2012.

SACCANI, S.; PANTANO, S.; NATOLI, G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. *Nature Immunology*, v. 3, n. 1, p. 69-75, 2002.

SADIK, C. D.; KIM, N. D.; LUSTER A. D. Neutrophils cascading their way to inflammation. *Trends in Immunology*. v. 32, n. 10, p. 452-460, 2011.

SAKLATVALA, J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. *Current Opinion in Pharmacology*, v. 4, n. 4, p. 372-377, 2004.

SALLES, A.; ROMANO, A.; FREUDENTHAL, R. Synaptic NF-kappa B pathway in neuronal plasticity and memory. *Journal of Physiology-Paris*, v. 108, p. 256-262, 2014.

SCHAPER, F.; ROSE-JOHN, S. Interleukin-6: biology, signaling and strategies of blockade. *Cytokine & Growth Factor Reviews*, v. 26, p. 475-487, 2015.

SCHMID-SCHÖBEIN, G. W. Analysis of Inflammation. *Annual Review of Biomedical Engineering*, v. 8, p. 93-151, 2006.

SEDDER, L. M.; MCDERMOTT, M. F. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. *Cytokine & Growth Factor Reviews*, v. 25, n. 4, p. 453-72, 2014.

SOEHNLEIN, O.; LINDBOM, L. Phagocyte partnership during the onset and resolution of inflammation. *Nature Reviews Immunology*, v. 10, p. 427-439, 2010.

STEWART, L.; KATIAL, R. K. Exhaled Nitric Oxide. *Immunology and Allergy Clinics of North America*, v. 32, n. 3, p. 347-362, 2012.

TRIPATHI, P.; TRIPATHI, P.; KASHYAP, L.; SINGH, V. The role of nitric oxide in inflammatory reactions. *FEMS Immunology and Medical Microbiology*, v. 51, p. 443-452, 2007.

VAN DER VEEN, B. S.; WINTHER, M. P. J.; HEERINGA, P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. *Antioxidants & Redox Signaling*, v. 11, n. 11, p. 1-39, 2009.

VANDEVYVER, S.; DEJAGER, L.; TUCKERMANN, J.; LIBERT, C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. *Endocrinology*, v 154, n. 3, p. 993-1007, 2013.

WALTZ, P.; ESCOBAR, D.; BOTERO, A. M.; ZUCKERBRAUN, B. S. Nitrate/nitrite as critical mediators to limit oxidative injury and inflammation. *Antioxidants & Redox Signaling*, v. 23, n. 4, p. 328-339, 2015.

WANG, Y.; CHEN, C.; LOAKE, G. J.; CHU, C. Nitric oxide: promoter or suppressor of programmed cell death?. *Protein & Cell*, v. 1, n. 2, p. 133-142, 2010.

WYATT, J. E.; PETTIT, W. L.; HARIRFOROOSH, S. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. *Pharmacogenomics Journal*, v. 12, n. 6, p. 462-467, 2012.

YOKOTA, T, WANG, Y. p38 MAP kinases in the heart. *Gene*, v. 575, n. 2, p. 369-376, 2016.

ZARUBIN, T.; HAN, J. Activation and signaling of the p38 MAP kinase pathway. *Cell Research*, v. 15, n. 1, p. 11-18, 2005.

**Bibliografia complementar****Seminários**